Trial
NCT00984152
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Rush University Medical Center
Collaborators
Merck Sharp & Dohme LLC
Condition
HIV-1 Infections
Intervention
TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
Why stopped
Decision not to go forth with study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-05-06